IOCAS-IR  > 实验海洋生物学重点实验室
Current advances in development of new docetaxel formulations
Zhang, Enhui1,2,3; Xing, Ronge1,2,3; Liu, Song1,2,3; Li, Pengcheng1,2,3
2019-03-04
Source PublicationEXPERT OPINION ON DRUG DELIVERY
ISSN1742-5247
Volume16Issue:3Pages:301-312
Corresponding AuthorXing, Ronge(xingronge@qdio.ac.cn) ; Li, Pengcheng(pcli@qdio.ac.cn)
AbstractIntroduction: Docetaxel (DTX) is one of the most important chemotherapeutic agents and has been widely used for treatment of various types of cancers. However, the clinical chemotherapy of DTX gives many undesirable side effects due to the usage of organic solvent in the injection and its low selectivity for tumor cells. With the evolution of pharmaceutical technologies, great efforts have been paid to develop new DTX formulations to overcome these problems. Areas covered: This review provided an overview of the preparation and activities of new DTX formulations, which were classified by administration methods, including injection, oral, transdermal and rectal administration. Besides, up to date information of the clinical status of new DTX formulations was summarized. We also discussed the challenges and perspectives of the future development of DTX formulations. Expert opinion: There have been numerous studies on new DTX-based formulations in recent years, and many of them exhibited significantly enhanced anti-tumor and targeting activity compared with DTX in preclinical studies. However, only a few entered clinical trials, and none has been approved into market. The clinical translation of experimental drug faces many hurdles, including the limited knowledge of nanomedicine and oncology, safety issues, controllable and reproducible production.
KeywordDocetaxel drug delivery system targeting liposome nanoparticle
DOI10.1080/17425247.2019.1583644
Indexed BySCI
Language英语
Funding ProjectNational Key R&D Program of China[2018YFC0311305] ; Special projects of Foshan science and technology innovation team[2017IT100054]
WOS Research AreaPharmacology & Pharmacy
WOS SubjectPharmacology & Pharmacy
WOS IDWOS:000461429100009
PublisherTAYLOR & FRANCIS LTD
Citation statistics
Cited Times:2[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.qdio.ac.cn/handle/337002/155223
Collection实验海洋生物学重点实验室
Corresponding AuthorXing, Ronge; Li, Pengcheng
Affiliation1.Chinese Acad Sci, Inst Oceanol, CAS Key Lab Expt Marine Biol, Qingdao, Peoples R China
2.Qingdao Natl Lab Marine Sci & Technol, Lab Marine Drugs & Bioprod, Qingdao, Peoples R China
3.Chinese Acad Sci, Ctr Ocean Mega Sci, Qingdao, Peoples R China
First Author AffilicationInstitute of Oceanology, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Oceanology, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Zhang, Enhui,Xing, Ronge,Liu, Song,et al. Current advances in development of new docetaxel formulations[J]. EXPERT OPINION ON DRUG DELIVERY,2019,16(3):301-312.
APA Zhang, Enhui,Xing, Ronge,Liu, Song,&Li, Pengcheng.(2019).Current advances in development of new docetaxel formulations.EXPERT OPINION ON DRUG DELIVERY,16(3),301-312.
MLA Zhang, Enhui,et al."Current advances in development of new docetaxel formulations".EXPERT OPINION ON DRUG DELIVERY 16.3(2019):301-312.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zhang, Enhui]'s Articles
[Xing, Ronge]'s Articles
[Liu, Song]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zhang, Enhui]'s Articles
[Xing, Ronge]'s Articles
[Liu, Song]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zhang, Enhui]'s Articles
[Xing, Ronge]'s Articles
[Liu, Song]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.